个人中心 - 老虎社区

IAN3114

IP属地：未知

帖子 · 6帖子 · 6
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- IAN3114IAN3114
  ·2021-12-11
  Good
  Microsoft stock jumped more than 2% in morning trading
  Microsoft stock jumped more than 2% in morning trading as Microsoft set to win EU antitrust nod for
  Microsoft stock jumped more than 2% in morning trading
  962 评论
  7
  分享
  举报
- IAN3114IAN3114
  ·2021-11-14
  Good for those vested
  Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.
  Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Mo
  Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.
  955 1
  4
  分享
  举报
- IAN3114IAN3114
  ·2021-10-04
  Hi
  前瞻：9月非农数据来袭！谭仔国际将于周四上市
  数据方面：中国9月财新服务业PMI、美国初请失业金人数、美国9月失业率、美国9月季调后非农就业人口即将揭晓事件方面：关注第21届欧佩克与非欧佩克产油国部长级会议、澳洲联储公布利率决议新
  前瞻：9月非农数据来袭！谭仔国际将于周四上市
  790 1
  5
  分享
  举报
- IAN3114IAN3114
  ·2021-10-03
  Hi
  非常抱歉，此主贴已删除
  685 评论
  7
  分享
  举报
- IAN3114IAN3114
  ·2021-09-26
  Hi
  非常抱歉，此主贴已删除
  745 1
  7
  分享
  举报
- IAN3114IAN3114
  ·2021-05-20
  Like and comment thanks
  非常抱歉，此主贴已删除
  445 3
  6
  分享
  举报
暂无粉丝

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3579340550920229","uuid":"3579340550920229","gmtCreate":1616290041675,"gmtModify":1616290041675,"name":"IAN3114","pinyin":"ian3114","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":5,"headSize":4,"tweetSize":6,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.12.17","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.03.23","exceedPercentage":"60.85%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":3,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":5,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":605238013,"gmtCreate":1639179075128,"gmtModify":1639179075241,"author":{"id":"3579340550920229","authorId":"3579340550920229","name":"IAN3114","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579340550920229","authorIdStr":"3579340550920229"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/605238013","repostId":"1173242614","repostType":4,"repost":{"id":"1173242614","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639149896,"share":"https://www.laohu8.com/m/news/1173242614?lang=&edition=full","pubTime":"2021-12-10 23:24","market":"us","language":"en","title":"Microsoft stock jumped more than 2% in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1173242614","media":"Tiger Newspress","summary":"Microsoft stock jumped more than 2% in morning trading as Microsoft set to win EU antitrust nod for ","content":"<p>Microsoft stock jumped more than 2% in morning trading&nbsp;as&nbsp;Microsoft set to win EU antitrust nod for $16 bln Nuance deal, sources said.</p>\n<p><img src=\"https://static.tigerbbs.com/f2b1206ee31bbf82c8f0f2186cf1d5d0\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n<p>U.S. software giant Microsoft Corp&nbsp;is set to secure unconditional EU antitrust approval for its $16 billion bid for artificial intelligence and speech technology firm Nuance Communications Inc, people familiar with the matter said.</p>\n<p>The deal, the latest in the tech industry, comes amid heightened regulatory scrutiny of takeovers by tech giants and acquisitions where nascent start-ups and potential rivals are shut down.</p>\n<p>Microsoft announced the deal in April which will boost its presence in cloud solutions for healthcare customers.</p>\n<p>The U.S. software giant is currently in talks with the British antitrust agency ahead of filing a request for approval of the deal, the sources said.</p>\n<p>The European Commission, which is scheduled to decide on the deal by Dec. 21, declined to comment. Microsoft also declined to comment.</p>\n<p>The company is also in preliminary discussions with the UK antitrust agency CMA ahead of a formal request for approval of the deal, the sources said.</p>\n<p>The deal has already received the regulatory green light in the United States and Australia, without remedies given.</p>\n<p>Nuance, known for pioneering speech technology and helping launch Apple Inc's&nbsp;virtual assistant, Siri, serves 77% of U.S. hospitals.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Microsoft stock jumped more than 2% in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMicrosoft stock jumped more than 2% in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-10 23:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Microsoft stock jumped more than 2% in morning trading&nbsp;as&nbsp;Microsoft set to win EU antitrust nod for $16 bln Nuance deal, sources said.</p>\n<p><img src=\"https://static.tigerbbs.com/f2b1206ee31bbf82c8f0f2186cf1d5d0\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n<p>U.S. software giant Microsoft Corp&nbsp;is set to secure unconditional EU antitrust approval for its $16 billion bid for artificial intelligence and speech technology firm Nuance Communications Inc, people familiar with the matter said.</p>\n<p>The deal, the latest in the tech industry, comes amid heightened regulatory scrutiny of takeovers by tech giants and acquisitions where nascent start-ups and potential rivals are shut down.</p>\n<p>Microsoft announced the deal in April which will boost its presence in cloud solutions for healthcare customers.</p>\n<p>The U.S. software giant is currently in talks with the British antitrust agency ahead of filing a request for approval of the deal, the sources said.</p>\n<p>The European Commission, which is scheduled to decide on the deal by Dec. 21, declined to comment. Microsoft also declined to comment.</p>\n<p>The company is also in preliminary discussions with the UK antitrust agency CMA ahead of a formal request for approval of the deal, the sources said.</p>\n<p>The deal has already received the regulatory green light in the United States and Australia, without remedies given.</p>\n<p>Nuance, known for pioneering speech technology and helping launch Apple Inc's&nbsp;virtual assistant, Siri, serves 77% of U.S. hospitals.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MSFT":"微软"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1173242614","content_text":"Microsoft stock jumped more than 2% in morning trading as Microsoft set to win EU antitrust nod for $16 bln Nuance deal, sources said.\n\nU.S. software giant Microsoft Corp is set to secure unconditional EU antitrust approval for its $16 billion bid for artificial intelligence and speech technology firm Nuance Communications Inc, people familiar with the matter said.\nThe deal, the latest in the tech industry, comes amid heightened regulatory scrutiny of takeovers by tech giants and acquisitions where nascent start-ups and potential rivals are shut down.\nMicrosoft announced the deal in April which will boost its presence in cloud solutions for healthcare customers.\nThe U.S. software giant is currently in talks with the British antitrust agency ahead of filing a request for approval of the deal, the sources said.\nThe European Commission, which is scheduled to decide on the deal by Dec. 21, declined to comment. Microsoft also declined to comment.\nThe company is also in preliminary discussions with the UK antitrust agency CMA ahead of a formal request for approval of the deal, the sources said.\nThe deal has already received the regulatory green light in the United States and Australia, without remedies given.\nNuance, known for pioneering speech technology and helping launch Apple Inc's virtual assistant, Siri, serves 77% of U.S. hospitals.","news_type":1,"symbols_score_info":{"MSFT":0.9}},"isVote":1,"tweetType":1,"viewCount":962,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873950945,"gmtCreate":1636848880106,"gmtModify":1636848880106,"author":{"id":"3579340550920229","authorId":"3579340550920229","name":"IAN3114","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579340550920229","authorIdStr":"3579340550920229"},"themes":[],"htmlText":"Good for those vested","listText":"Good for those vested","text":"Good for those vested","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/873950945","repostId":"1102251183","repostType":4,"repost":{"id":"1102251183","kind":"news","pubTimestamp":1636772424,"share":"https://www.laohu8.com/m/news/1102251183?lang=&edition=full","pubTime":"2021-11-13 11:00","market":"us","language":"en","title":"Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.","url":"https://stock-news.laohu8.com/highlight/detail?id=1102251183","media":"Barrons","summary":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Mo","content":"<p>Pfizer’s&nbsp;chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p>\n<p>“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p>\n<p>Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p>\n<p>Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p>\n<p>In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p>\n<p>The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p>\n<p>Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like&nbsp;Johnson &amp; Johnson&nbsp;(JNJ) and&nbsp;Eli Lilly&nbsp;(LLY).</p>\n<p>The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p>\n<p>The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p>\n<p>The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p>\n<p>While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech&nbsp;BioNTech&nbsp;(BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p>\n<p>In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p>\n<p>The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p>\n<p>“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p>\n<p>Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p>\n<p>“[Pfizer’s] pharmaceutical R&amp;D is better than people had thought.”</p>\n<p>The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p>\n<p>“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p>\n<p>Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from&nbsp;Merck&nbsp;(MRK).</p>\n<p>“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&amp;D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p>\n<p>Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p>\n<p>“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p>\n<p>That makes a bet on Pfizer a long-term play. In the meantime, the experience of&nbsp;Moderna&nbsp;(MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p>\n<p>Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p>\n<p>Moderna shares are down more than 40% over the past three months.</p>\n<p>As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p>\n<p>When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p>\n<p>That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p>\n<p>Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p>\n<p>Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p>\n<p>An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-13 11:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that...</p>\n\n<a href=\"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102251183","content_text":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.\n“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.\nTwo years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.\nBourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.\nIn a cover story in November 2019, Barron’s argued that Bourla and Dolsten could pull it off.\nThe new antiviral data reaffirms the case for Pfizer that Barron’s made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.\nPfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).\nThe Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.\nThe worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.\nThe success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.\nWhile Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.\nIn the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.\nThe antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.\n“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.\nDolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.\n“[Pfizer’s] pharmaceutical R&D is better than people had thought.”\nThe protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.\n“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.\nPfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).\n“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.\nChen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.\n“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”\nThat makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.\nBiden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”\nModerna shares are down more than 40% over the past three months.\nAs the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling Barron’s that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.\nWhen it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.\nThat contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.\nDolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”\nSuch a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.\nAn aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":955,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":867526053,"gmtCreate":1633302994779,"gmtModify":1633302994868,"author":{"id":"3579340550920229","authorId":"3579340550920229","name":"IAN3114","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579340550920229","authorIdStr":"3579340550920229"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/867526053","repostId":"1135847352","repostType":2,"repost":{"id":"1135847352","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1633301975,"share":"https://www.laohu8.com/m/news/1135847352?lang=&edition=full","pubTime":"2021-10-04 06:59","market":"us","language":"zh","title":"前瞻：9月非农数据来袭！谭仔国际将于周四上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1135847352","media":"老虎资讯综合","summary":"数据方面：中国9月财新服务业PMI、美国初请失业金人数、美国9月失业率、美国9月季调后非农就业人口即将揭晓\n\n\n 事件方面：关注第21届欧佩克与非欧佩克产油国部长级会议、澳洲联储公布利率决议\n\n\n 新","content":"<blockquote>\n 数据方面：中国9月财新服务业PMI、美国初请失业金人数、美国9月失业率、美国9月季调后非农就业人口即将揭晓\n</blockquote>\n<blockquote>\n 事件方面：关注第21届欧佩克与非欧佩克产油国部长级会议、澳洲联储公布利率决议\n</blockquote>\n<blockquote>\n 新股方面：谭仔国际、健身器材和健康内容订阅服务商IFIT等多只港美新股上市\n</blockquote>\n<blockquote>\n 财报方面：饮料巨头百事可乐、牛仔品牌李维斯将发财报\n</blockquote>\n<p><b>周一(10月4日)关键词：欧元区投资者信心、OPEC+部长级会议</b></p>\n<p><img src=\"https://static.tigerbbs.com/6e60311d02c67b23d8bd34515a04f968\" tg-width=\"680\" tg-height=\"230\" referrerpolicy=\"no-referrer\"><b>周一，事件方面，</b>市场中所有目光都集中在石油输出国组织和以俄罗斯为首的合作伙伴(OPEC+)将于10月4日举行的会议上。除了现有协议允诺的将11月和12月产量每月提高40万桶/日外，产油国料将讨论其他选项。</p>\n<p>四位OPEC+消息人士表示，进一步增加石油产量是一种可能，但没有人给出具体数量或具体月份。另一位OPEC+消息人士表示，未来一个月可能增加80万桶/日，而之后一个月可能为不增产。</p>\n<p><b>经济数据方面，</b>关注欧元区10月Sentix投资者信心指数。</p>\n<p><b>周二(10月5日)关键词：澳洲联储决议、美国ISM非制造业PMI、API库存</b></p>\n<p><b>周二，事件方面，关注澳洲联储决议，</b>澳洲联储9月政策会议纪要显示，澳洲联储担心，一旦抗疫封锁开始放松，Delta变异毒株传播可能会放缓经济复苏，尽管该央行仍预计明年经济将恢复强劲增长。委员会考虑推迟将购债计划缩减10亿澳元(7.27亿美元)至每周40亿澳元的计划。</p>\n<p><b>经济数据方面，</b>关注美国ISM非制造业PMI。</p>\n<p><b>财报方面，饮料巨头<a href=\"https://laohu8.com/S/PEP\">百事可乐</a></b>将于周二盘前公布财报。</p>\n<p><b>周三(10月6日)关键词：新西兰联储决议、美国ADP、EIA、博斯蒂克</b><img src=\"https://static.tigerbbs.com/90f66ccdd4037e85a30bf2ff38185cf9\" tg-width=\"680\" tg-height=\"192\" referrerpolicy=\"no-referrer\"><b>周三，事件方面，关注新西兰联储公布利率决议。</b>新西兰二季度GDP环比增长2.8%，同比增长17.4%。外界普遍认为，新西兰联储极有可能在本周开始加息，并在11月再次加息。新西兰联储已经非常坚定地走上了收紧货币政策的道路。</p>\n<p><b>经济数据方面，投资者重点关注美国9月ADP就业人数、美国至10月1日当周EIA原油库存。</b></p>\n<p><b>财报方面，美股<a href=\"https://laohu8.com/S/STZ\">星座品牌</a>将于周三盘前、<a href=\"https://laohu8.com/S/LEVI\">李维斯</a>于盘后公布财报。</b></p>\n<p><b>新股方面，</b>健身器材和健康内容订阅服务商<a href=\"https://laohu8.com/S/IFIT.US\">iFIT Health &amp; Fitness Inc.</a>将在纳斯达克上市，股票代码为IFIT。该公司的估值可能高达67亿美元。</p>\n<p>IFit被认为是Peloton Interactive(PTON)更实惠的替代品。该公司提供iFit、NordicTrack、ProForm和FreeMotion等品牌的跑步机、自行车和椭圆机等设备。IFit用户可以在跑步机、自行车或该公司的Vault互动家庭健身房上接受流媒体教练指导。个人访问iFit点播内容的月费为15美元，五口之家的家庭月费为39美元。</p>\n<p><b>周四(10月7日)关键词：中国外储、美国初请、连恩</b><img src=\"https://static.tigerbbs.com/a4e00bcbb1f4e6aed6b75d44d691d91c\" tg-width=\"680\" tg-height=\"173\" referrerpolicy=\"no-referrer\"><b>周四，经济数据方面，关注中国9月外汇储备。</b>国家外汇管理局副局长、新闻发言人王春英称，中国8月外储规模连续4个月稳定在3.2万亿元关口上方，年内人民币汇率将基本保持稳定，且境内股市、债市对外资仍具较强吸引力，多重因素将继续支撑外储规模保持基本稳定。</p>\n<p><b>此外，关注美国初请失业金人数。</b>美国首次申请失业救济人数出人意料的连续三周上升，这可能反映出劳动力市场状况恶化以及这个每周数据的高波动性。首次申请失业救济人数上升可能凸显出每周数据的波动，因为雇主迫切希望招聘更多员工，并且能够留住现有的人手。不过，首次申请失业救济人数仍徘徊在疫情以来的低点附近。</p>\n<p><b>财报方面，</b>美股<a href=\"https://laohu8.com/S/CAG\">康尼格拉</a>将于周四盘前发布财报。</p>\n<p><b>新股方面，</b>港股<a href=\"https://laohu8.com/S/02217\">谭仔国际</a>预期将于周三（10月6日）开启暗盘，并于周四（10月7日）正式上市。该香港米线快餐品牌，又被视为港版沙县。</p>\n<p>美股较多新股上市，包括<a href=\"https://laohu8.com/S/CING\">CINGULATE INC.</a>、<a href=\"https://laohu8.com/S/LTH\">Life Time Group Holdings, Inc.</a>、<a href=\"https://laohu8.com/S/THRX\">THESEUS PHARMACEUTICALS, INC.</a>。</p>\n<p><b>周五(10月8日)关键词：中国财新服务业PMI、中国社融、美国非农、加拿大就业</b><img src=\"https://static.tigerbbs.com/98e08bf599878d94f848521b1bd6efed\" tg-width=\"680\" tg-height=\"306\" referrerpolicy=\"no-referrer\"><b>周五，经济数据方面，关注中国财新服务业PMI。</b>中国8月服务业供给、需求出现不同程度收缩，因疫情反弹影响了服务业的正常生产经营。不过，随着此轮疫情得到有效控制及中秋、国庆假日临近，企业对近期服务业市场恢复较为乐观。<b>另外，预计中国9月社会融资规模将于周六公布。</b></p>\n<p><b>此外，关注美国非农。</b>美联储主席鲍威尔表示，美国经济距离实现充分就业仍很遥远，而充分就业是美联储加息门槛的关键组成部分。这加重了将于10月8日发布的美国9月非农就业报告的份量。该数据可能会显示，新冠Delta变体的影响是否比美联储官员在夏季早些时候预期的更深。</p>\n<p>新股方面，美股<a href=\"https://laohu8.com/S/ISO\">IsoPlexis Corp.</a>将上市。</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>前瞻：9月非农数据来袭！谭仔国际将于周四上市</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n前瞻：9月非农数据来袭！谭仔国际将于周四上市\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2021-10-04 06:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<blockquote>\n 数据方面：中国9月财新服务业PMI、美国初请失业金人数、美国9月失业率、美国9月季调后非农就业人口即将揭晓\n</blockquote>\n<blockquote>\n 事件方面：关注第21届欧佩克与非欧佩克产油国部长级会议、澳洲联储公布利率决议\n</blockquote>\n<blockquote>\n 新股方面：谭仔国际、健身器材和健康内容订阅服务商IFIT等多只港美新股上市\n</blockquote>\n<blockquote>\n 财报方面：饮料巨头百事可乐、牛仔品牌李维斯将发财报\n</blockquote>\n<p><b>周一(10月4日)关键词：欧元区投资者信心、OPEC+部长级会议</b></p>\n<p><img src=\"https://static.tigerbbs.com/6e60311d02c67b23d8bd34515a04f968\" tg-width=\"680\" tg-height=\"230\" referrerpolicy=\"no-referrer\"><b>周一，事件方面，</b>市场中所有目光都集中在石油输出国组织和以俄罗斯为首的合作伙伴(OPEC+)将于10月4日举行的会议上。除了现有协议允诺的将11月和12月产量每月提高40万桶/日外，产油国料将讨论其他选项。</p>\n<p>四位OPEC+消息人士表示，进一步增加石油产量是一种可能，但没有人给出具体数量或具体月份。另一位OPEC+消息人士表示，未来一个月可能增加80万桶/日，而之后一个月可能为不增产。</p>\n<p><b>经济数据方面，</b>关注欧元区10月Sentix投资者信心指数。</p>\n<p><b>周二(10月5日)关键词：澳洲联储决议、美国ISM非制造业PMI、API库存</b></p>\n<p><b>周二，事件方面，关注澳洲联储决议，</b>澳洲联储9月政策会议纪要显示，澳洲联储担心，一旦抗疫封锁开始放松，Delta变异毒株传播可能会放缓经济复苏，尽管该央行仍预计明年经济将恢复强劲增长。委员会考虑推迟将购债计划缩减10亿澳元(7.27亿美元)至每周40亿澳元的计划。</p>\n<p><b>经济数据方面，</b>关注美国ISM非制造业PMI。</p>\n<p><b>财报方面，饮料巨头<a href=\"https://laohu8.com/S/PEP\">百事可乐</a></b>将于周二盘前公布财报。</p>\n<p><b>周三(10月6日)关键词：新西兰联储决议、美国ADP、EIA、博斯蒂克</b><img src=\"https://static.tigerbbs.com/90f66ccdd4037e85a30bf2ff38185cf9\" tg-width=\"680\" tg-height=\"192\" referrerpolicy=\"no-referrer\"><b>周三，事件方面，关注新西兰联储公布利率决议。</b>新西兰二季度GDP环比增长2.8%，同比增长17.4%。外界普遍认为，新西兰联储极有可能在本周开始加息，并在11月再次加息。新西兰联储已经非常坚定地走上了收紧货币政策的道路。</p>\n<p><b>经济数据方面，投资者重点关注美国9月ADP就业人数、美国至10月1日当周EIA原油库存。</b></p>\n<p><b>财报方面，美股<a href=\"https://laohu8.com/S/STZ\">星座品牌</a>将于周三盘前、<a href=\"https://laohu8.com/S/LEVI\">李维斯</a>于盘后公布财报。</b></p>\n<p><b>新股方面，</b>健身器材和健康内容订阅服务商<a href=\"https://laohu8.com/S/IFIT.US\">iFIT Health &amp; Fitness Inc.</a>将在纳斯达克上市，股票代码为IFIT。该公司的估值可能高达67亿美元。</p>\n<p>IFit被认为是Peloton Interactive(PTON)更实惠的替代品。该公司提供iFit、NordicTrack、ProForm和FreeMotion等品牌的跑步机、自行车和椭圆机等设备。IFit用户可以在跑步机、自行车或该公司的Vault互动家庭健身房上接受流媒体教练指导。个人访问iFit点播内容的月费为15美元，五口之家的家庭月费为39美元。</p>\n<p><b>周四(10月7日)关键词：中国外储、美国初请、连恩</b><img src=\"https://static.tigerbbs.com/a4e00bcbb1f4e6aed6b75d44d691d91c\" tg-width=\"680\" tg-height=\"173\" referrerpolicy=\"no-referrer\"><b>周四，经济数据方面，关注中国9月外汇储备。</b>国家外汇管理局副局长、新闻发言人王春英称，中国8月外储规模连续4个月稳定在3.2万亿元关口上方，年内人民币汇率将基本保持稳定，且境内股市、债市对外资仍具较强吸引力，多重因素将继续支撑外储规模保持基本稳定。</p>\n<p><b>此外，关注美国初请失业金人数。</b>美国首次申请失业救济人数出人意料的连续三周上升，这可能反映出劳动力市场状况恶化以及这个每周数据的高波动性。首次申请失业救济人数上升可能凸显出每周数据的波动，因为雇主迫切希望招聘更多员工，并且能够留住现有的人手。不过，首次申请失业救济人数仍徘徊在疫情以来的低点附近。</p>\n<p><b>财报方面，</b>美股<a href=\"https://laohu8.com/S/CAG\">康尼格拉</a>将于周四盘前发布财报。</p>\n<p><b>新股方面，</b>港股<a href=\"https://laohu8.com/S/02217\">谭仔国际</a>预期将于周三（10月6日）开启暗盘，并于周四（10月7日）正式上市。该香港米线快餐品牌，又被视为港版沙县。</p>\n<p>美股较多新股上市，包括<a href=\"https://laohu8.com/S/CING\">CINGULATE INC.</a>、<a href=\"https://laohu8.com/S/LTH\">Life Time Group Holdings, Inc.</a>、<a href=\"https://laohu8.com/S/THRX\">THESEUS PHARMACEUTICALS, INC.</a>。</p>\n<p><b>周五(10月8日)关键词：中国财新服务业PMI、中国社融、美国非农、加拿大就业</b><img src=\"https://static.tigerbbs.com/98e08bf599878d94f848521b1bd6efed\" tg-width=\"680\" tg-height=\"306\" referrerpolicy=\"no-referrer\"><b>周五，经济数据方面，关注中国财新服务业PMI。</b>中国8月服务业供给、需求出现不同程度收缩，因疫情反弹影响了服务业的正常生产经营。不过，随着此轮疫情得到有效控制及中秋、国庆假日临近，企业对近期服务业市场恢复较为乐观。<b>另外，预计中国9月社会融资规模将于周六公布。</b></p>\n<p><b>此外，关注美国非农。</b>美联储主席鲍威尔表示，美国经济距离实现充分就业仍很遥远，而充分就业是美联储加息门槛的关键组成部分。这加重了将于10月8日发布的美国9月非农就业报告的份量。该数据可能会显示，新冠Delta变体的影响是否比美联储官员在夏季早些时候预期的更深。</p>\n<p>新股方面，美股<a href=\"https://laohu8.com/S/ISO\">IsoPlexis Corp.</a>将上市。</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/46744ceebcd5f9f6cbe09f85295d7cfe","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯",".SPX":"S&P 500 Index"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1135847352","content_text":"数据方面：中国9月财新服务业PMI、美国初请失业金人数、美国9月失业率、美国9月季调后非农就业人口即将揭晓\n\n\n 事件方面：关注第21届欧佩克与非欧佩克产油国部长级会议、澳洲联储公布利率决议\n\n\n 新股方面：谭仔国际、健身器材和健康内容订阅服务商IFIT等多只港美新股上市\n\n\n 财报方面：饮料巨头百事可乐、牛仔品牌李维斯将发财报\n\n周一(10月4日)关键词：欧元区投资者信心、OPEC+部长级会议\n周一，事件方面，市场中所有目光都集中在石油输出国组织和以俄罗斯为首的合作伙伴(OPEC+)将于10月4日举行的会议上。除了现有协议允诺的将11月和12月产量每月提高40万桶/日外，产油国料将讨论其他选项。\n四位OPEC+消息人士表示，进一步增加石油产量是一种可能，但没有人给出具体数量或具体月份。另一位OPEC+消息人士表示，未来一个月可能增加80万桶/日，而之后一个月可能为不增产。\n经济数据方面，关注欧元区10月Sentix投资者信心指数。\n周二(10月5日)关键词：澳洲联储决议、美国ISM非制造业PMI、API库存\n周二，事件方面，关注澳洲联储决议，澳洲联储9月政策会议纪要显示，澳洲联储担心，一旦抗疫封锁开始放松，Delta变异毒株传播可能会放缓经济复苏，尽管该央行仍预计明年经济将恢复强劲增长。委员会考虑推迟将购债计划缩减10亿澳元(7.27亿美元)至每周40亿澳元的计划。\n经济数据方面，关注美国ISM非制造业PMI。\n财报方面，饮料巨头百事可乐将于周二盘前公布财报。\n周三(10月6日)关键词：新西兰联储决议、美国ADP、EIA、博斯蒂克周三，事件方面，关注新西兰联储公布利率决议。新西兰二季度GDP环比增长2.8%，同比增长17.4%。外界普遍认为，新西兰联储极有可能在本周开始加息，并在11月再次加息。新西兰联储已经非常坚定地走上了收紧货币政策的道路。\n经济数据方面，投资者重点关注美国9月ADP就业人数、美国至10月1日当周EIA原油库存。\n财报方面，美股星座品牌将于周三盘前、李维斯于盘后公布财报。\n新股方面，健身器材和健康内容订阅服务商iFIT Health & Fitness Inc.将在纳斯达克上市，股票代码为IFIT。该公司的估值可能高达67亿美元。\nIFit被认为是Peloton Interactive(PTON)更实惠的替代品。该公司提供iFit、NordicTrack、ProForm和FreeMotion等品牌的跑步机、自行车和椭圆机等设备。IFit用户可以在跑步机、自行车或该公司的Vault互动家庭健身房上接受流媒体教练指导。个人访问iFit点播内容的月费为15美元，五口之家的家庭月费为39美元。\n周四(10月7日)关键词：中国外储、美国初请、连恩周四，经济数据方面，关注中国9月外汇储备。国家外汇管理局副局长、新闻发言人王春英称，中国8月外储规模连续4个月稳定在3.2万亿元关口上方，年内人民币汇率将基本保持稳定，且境内股市、债市对外资仍具较强吸引力，多重因素将继续支撑外储规模保持基本稳定。\n此外，关注美国初请失业金人数。美国首次申请失业救济人数出人意料的连续三周上升，这可能反映出劳动力市场状况恶化以及这个每周数据的高波动性。首次申请失业救济人数上升可能凸显出每周数据的波动，因为雇主迫切希望招聘更多员工，并且能够留住现有的人手。不过，首次申请失业救济人数仍徘徊在疫情以来的低点附近。\n财报方面，美股康尼格拉将于周四盘前发布财报。\n新股方面，港股谭仔国际预期将于周三（10月6日）开启暗盘，并于周四（10月7日）正式上市。该香港米线快餐品牌，又被视为港版沙县。\n美股较多新股上市，包括CINGULATE INC.、Life Time Group Holdings, Inc.、THESEUS PHARMACEUTICALS, INC.。\n周五(10月8日)关键词：中国财新服务业PMI、中国社融、美国非农、加拿大就业周五，经济数据方面，关注中国财新服务业PMI。中国8月服务业供给、需求出现不同程度收缩，因疫情反弹影响了服务业的正常生产经营。不过，随着此轮疫情得到有效控制及中秋、国庆假日临近，企业对近期服务业市场恢复较为乐观。另外，预计中国9月社会融资规模将于周六公布。\n此外，关注美国非农。美联储主席鲍威尔表示，美国经济距离实现充分就业仍很遥远，而充分就业是美联储加息门槛的关键组成部分。这加重了将于10月8日发布的美国9月非农就业报告的份量。该数据可能会显示，新冠Delta变体的影响是否比美联储官员在夏季早些时候预期的更深。\n新股方面，美股IsoPlexis Corp.将上市。","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,".SPX":0.9}},"isVote":1,"tweetType":1,"viewCount":790,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":867199204,"gmtCreate":1633223454062,"gmtModify":1633223454151,"author":{"id":"3579340550920229","authorId":"3579340550920229","name":"IAN3114","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579340550920229","authorIdStr":"3579340550920229"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/867199204","repostId":"2172964531","repostType":4,"isVote":1,"tweetType":1,"viewCount":685,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":868346232,"gmtCreate":1632614911726,"gmtModify":1632652894634,"author":{"id":"3579340550920229","authorId":"3579340550920229","name":"IAN3114","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579340550920229","authorIdStr":"3579340550920229"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/868346232","repostId":"2170611559","repostType":4,"isVote":1,"tweetType":1,"viewCount":745,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":197652628,"gmtCreate":1621466095764,"gmtModify":1634189024634,"author":{"id":"3579340550920229","authorId":"3579340550920229","name":"IAN3114","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579340550920229","authorIdStr":"3579340550920229"},"themes":[],"htmlText":"Like and comment thanks","listText":"Like and comment thanks","text":"Like and comment thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/197652628","repostId":"1126891253","repostType":4,"isVote":1,"tweetType":1,"viewCount":445,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"followers","isTTM":false}